Christian Tinel on why IBD's unmet need comes down to one thing: an oral therapy with biologic-like efficacy and better safety.
Christian Thienel
Advertisement
Christian Thienel is director at Back Bay Life Sciences.
Articles by Christian Thienel
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Novartis, Bristol Myers Pause Autoimmune CAR-T Trials Over Safety Concerns: Report
2
Pharmaceutical Executive Daily: Novartis and BMS Halt CAR-T Trials
3
Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTech Partnership, RedHill Acquires Commercialization Rights to Rebyota & Clenpiq
4
Redefining Medical Strategy in Obesity Through Real-World iNSIGHTS
5